NCT02834052 - Pembrolizumab + Poly-ICLC in MRP Colon Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

July 29, 2022

Study Completion Date

July 29, 2022

Conditions

Metastatic Colon CancerSolid Tumor

Interventions

DRUG

pembrolizumab

200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle

DRUG

Poly-ICLC

"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"

Trial Locations (1)

30912

Georgia Cancer Center at Augusta University, Augusta